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INTRODUCTION
Author Manuscript Published OnlineFirst on September 12, 2011; DOI: 10.1158/0008-5472. Adenovirus type 5 E1A (E1A) was originally recognized as an oncogene that could facilitate oncogenic transformation by other viral and cellular oncogenes. However, E1A has not been associated with human malignancies despite extensive efforts to identify such a link (1) . Instead, E1A was shown to have anti-tumor activities by reversing the transformed phenotype, inhibiting metastasis, and inducing apoptosis in multiple transformed rodent cells and human cancer cell lines (2) (3) (4) (5) (6) . In addition to the tumor suppressor activities, expression of the E1A gene in stably transfected normal fibroblasts and human cancer cells has also been shown to induce sensitization among different categories of anticancer drugs in vitro, including etoposide, cisplatin, doxorubicin, gemcitabine, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), histone deacetylase (HDAC) inhibitors and paclitaxel in normal fibroblasts, sarcoma, non-small cell lung, hepatocellular, ovarian and breast cancer cells (7) (8) (9) (10) (11) (12) . Animal studies also showed that the combination of systemic E1A gene therapy with paclitaxel significantly enhanced paclitaxel-induced apoptosis and prolonged survival rates in the animal orthotopic model in vivo (11, 13) . Therefore, E1A is now considered a tumor suppressor gene and has been tested in multiple clinical trials in a gene therapy setting for patients with breast (14, 15) , ovarian (2, 14) , and head and neck cancers (15, 16) . A clinical study using E1A gene therapy combined with paclitaxel has been initiated for ovarian cancer. Thus, it is critical and timely to understand the detailed molecular mechanisms that associate with E1A-mediated chemosensitization, and future clinical trials using the combination of chemotherapy with E1A gene therapy can be further improved.
One of the molecular mechanisms by which E1A induces chemosensitization is downregulation of Her-2/neu overexpression (8, 11) . Recently, inhibition of Akt and activation of p38 was reported to provide a general cellular mechanism for E1A-mediated chemosensitization (9, 17) . Regulation of some critical tumor suppressors was also proposed as being involved in E1A-induced chemosensitization, such as p53 and p19ARF (18) , the proapoptotic protein Bax, caspase 9, and a yet-unidentified inhibitor that ordinarily provides protection against cell death (11, (19) (20) (21) (22) .
Forkhead box O-class (FOXO) transcription factors include FOXO1 (Forkhead in rhabdomyosarcoma, FKHR), FOXO3a (FKHR-like 1, FKHRL1), and FOXO4 (acute lymphocytic leukemia-fused gene from chromosome X, AFX). The FOXOs activate and/or repress transcription of genes involved in metabolism, apoptosis, DNA damage repair, and cell cycle progression (23) . For example, FOXO3a has been shown to elevate p27 kip expression and induce cell cycle arrest (24) . FOXO3a and FOXO4 have also been shown to inhibit the cell cycle through down-regulation of cyclin D by a p27 kip -independent mechanism (25, 26). In breast cancer, FOXO3a has been shown to up-regulate Bim, a pro-apoptotic BH3 only protein (25, 27).
The activity of the FOXOs can be inhibited by activating the phosphoinositide 3'-kinase (PI3K)/Akt pathway. FOXO3a can be phosphorylated by Akt at three conserved serine/threonine residues (Thr32, Ser253, and Ser315), and it subsequently translocates from the nucleus to the cytoplasm, where it is retained by binding to the 14-3-3 protein (28). FOXO3a activity can also be inhibited by the IțB kinase (IKK) signaling pathway. IKK physically interacts with and phosphorylates FOXO3a independently of Akt, which causes nuclear exclusion of FOXO3a and subsequently proteolysis of FOXO3a via the ȕTrCP-mediated ubiquitin (Ub)-dependent proteasome pathway (29) . Recently, Erk was also known to phosphorylate FOXO3a at Ser294, Ser344 and Ser 425 sites which enhance interaction with the E3 Ub ligase MDM2, resulting in FOXO3a degradation (30) . However, the biological function and detailed molecular mechanism of FOXO3a proteolysis in E1A-mediated chemosensitization are still unclear. 6 In an attempt to understand the molecular mechanism of E1A-mediated chemosensitization, we found that FOXO3a is critical to that process. E1A stabilizes FOXO3a by preventing ȕTrCP-mediated Ub-dependent proteolysis through inhibiting the phosphorylation of FOXO3a at Ser644
by IKKȕ. E1A induces the expression of PP2A (a protein phosphatase involved in multiple cellular functions, including chemosensitization), which inhibits transforming growth factor ȕ-activated kinase 1 (TAK1)-activated IKK signaling, therefore stabilizing FOXO3a and inducing chemosensitization.
MATERIALS AND METHODS
Cell Lines, DNA Constructs, and Antibodies Cell lines MDA-MB-231, HeLa and MDA-157 cells were purchased from ATCC and grown in Dulbecco's modified Eagle's medium (DMEM)/F12 supplemented with 10% fetal bovine serum. The human breast cancer cell line MDA-MB-231 and its E1A/vector-stable transfectants have been described previously (31) . The transfectants were grown under the same conditions as the controls, except that G418 was added to the culture medium. Cell lines have been Recombinant human TNFα was purchased from Roche. MG132 was purchased from Sigma.
Immunoprecipitation and Western Blotting
Cells were washed twice with PBS, scraped into 500 μl of lysis buffer, and incubated on ice for 20 min. After centrifugation at 14,000 × g for 10 min, 1.5 mg of each supernatant was preincubated with 2 μg of immunoglobulin G and 50 μl of protein G for 1 h at 4°C.
Immunoprecipitation was performed overnight with 2 μg antibody and 50 μl of protein G. The immunocomplex was washed five times with lysis buffer, dissolved in loading buffer, subjected to SDS-PAGE, and transferred onto nitrocellulose membranes. The membranes were blocked with 5% nonfat dry milk in PBS containing 0.05% Tween 20 and incubated with primary antibodies, followed by secondary antibodies (Jackson ImmunoResearch Laboratories). The immunoblots were visualized with enhanced chemiluminescence (Amersham). 
Paclitaxel-Induced Cell Death

Orthotopic Breast Tumor Growth Assay
Six-week-old female SCID mice were orthotopically inoculated with tumor cells into the mammary fat pad and treated with vehicle or paclitaxel as described previously (9) . Tumor development was followed in individual animals (eight per group) by measuring tumor length (L) and width (W) with calipers every 3 days. Tumor volume was calculated with the formula LW 2 /2.
All animal work and care was performed in accordance with protocols approved by the Institutional Animal Care and Use Committee of China Medical University. E1A gene therapy has been shown to induce chemosensitization among different chemotherapeutic agents, including paclitaxel in breast and ovarian cancers (33) . It has been shown that resistance to paclitaxel occurs in cells expressing low level of FOXO3a (34) . We therefore asked whether FOXO3a may contribute to E1A-mediated chemosensitization. To this end, we examined the effects of E1A on FOXO3a expression in various types of cancer cells including MDA-MB-231, HeLa and MDA-MB-157 and found that expression of FOXO3a was significantly increased in E1A-transfected cells (Fig. 1A) . We found that FOXO3a-regulated apoptotic genes, such as FasL and p27, were increased in E1A-transfected cells and decreased by Figure 1D ). We therefore concluded that FOXO3a is required for the E1A-mediated chemosensitization to paclitaxel.
RESULTS
FOXO3a is critical for E1A-mediated chemosensitization
E1A prevents Ubiquitin-dependent proteolysis of FOXO3a
Posttranslational modification and regulation of FOXO3a protein stability are critical for FOXO3a activity (29 Interestingly, TNFα-induced binding between FOXO3a and ȕTrCP was significantly reduced in E1A-expressing cells (Fig. 2C ). In addition, ȕTrCP was shown to be required for maintenance of low FOXO3a expression by using siRNA of ȕTrCP. Transfection with siȕTrCP increased FOXO3a expression in 231/vector but not in 231/E1A cells (Fig. 2D) . Also, knockdown of ȕTrCP abolished the association between FOXO3a and ȕTrCP (Fig. 2D) . Taken together, these results suggest that E1A inhibits interaction of FOXO3a and ȕTrCP which may prevent from FOXO3a degradation.
Inhibition of TAK1-IKK signaling is required for E1A-mediated prevention of ȕTrCP/FOXO3a interaction and chemosensitization
It is known that ȕTrCP interacts with FOXO3 and induces its ubiquitin-dependent degradation in an IKKȕ phosphorylation dependent manner (29) . To define whether E1A- (Fig. 3B) . Furthermore, transfection with the HA-TAK1 expression vector significantly increased phosphorylation of IKK and the E1A-mediated downregulation of p-IKK was overcome by the forced expression of HA-TAK1 (Fig. 3C, left panel) . Experiments were also performed to ascertain whether TAK1 is involved in E1A-mediated FOXO3a interaction with ȕTrCP and chemosensitization. Forced expression of HA-TAK1 significantly increased the interaction between FOXO3a and ȕTrCP in 231/vector cells and the E1A-mediated inhibition effect was also recovered by exogenous expression of HA-TAK1 (Fig. 3C, right panel) .
Consistently, E1A-mediated chemosensitization to paclitaxel was also significantly impaired by expression of TAK1 (Fig. 3D) . Taken together, these data indicate that TAK1, the upstream kinase of IKK, is a critical regulator for E1A-repressed FOXO3a interaction with ȕTrCP and is required for E1A-mediated chemosensitization.
E1A-induced PP2A expression is required for regulation of TAK1-IKK signaling, ȕTrCP/FOXO3a interaction and chemosensitization
Phosphorylation of protein kinases are tightly regulated by related protein phosphatases, and it has been reported that E1A increases the expression of PP2A/C, the catalytic subunit of PP2A (14) . Since E1A inhibits TAK1 phosphorylation, we asked whether PP2A might be involved in E1A-mediated dephosphorylation of TAK1 and IKK and FOXO3a stabilization. To this end, 231/vector and 231/E1A cells were treated with the phosphatase inhibitor okadaic acid (OA). We found that E1A-mediated inhibition of TNFα-induced TAK1 phosphorylation was restored by OA treatment, as were E1A-mediated inhibition of IKK phosphorylation and the interaction between FOXO3a and ȕTrCP (Fig. 4A) . Consistently, E1A-induced chemosensitization was also decreased in 231/E1A cells by treatment with OA (Fig. 4B) . We next examined whether PP2A binds to TAK1. As shown in Fig. 4D ). These findings indicated that E1A-induced PP2A/C expression is required for regulation of TAK1/IKK signaling, ȕTrCP/FOXO3a interaction, and chemosensitization.
In summary, we found that FOXO3a is critical for E1A-mediated chemosensitization. E1A stabilizes FOXO3a by inducing the expression of PP2A/C and results in enhanced PP2A phosphatase activity. The enhanced PP2A/C interacts and dephosphorylates TAK1 to inactivate TAK1, which also renders inactivation of IKKȕ, therefore inhibiting IKKȕ-mediated interaction between ȕTrCP and FOXO3a and preventing ȕTrCP-induced FOXO3a degradation (Fig. 5) . E1A is associated with many anti-tumor activities and has been tested in multiple clinical trials.
Studies showed that although E1A gene therapy is safe and well tolerated, the tumor response to it is only modest (14-16). However, E1A has been shown to induce sensitization to apoptosis induced by different categories of anticancer drugs; therefore, one improvement that might render E1A more useful as an anticancer therapy is the combination of E1A gene therapy with conventional chemotherapy. Paclitaxel is a front-line chemotherapeutic agent for the treatment of human breast and ovarian cancer. One of the mechanisms that paclitaxel induces apoptosis in cancer cells is through increasing Bim (pro-apoptotic BH3-only protein) expression by activated FOXO3a activity (34) . In the current study, we found that E1A can stabilize FOXO3a, therefore sensitizing MDA-MB-231 breast cancer cells to paclitaxel-induced apoptosis both in vitro and in vivo. This result provides a molecular mechanism for stronger anti-tumor strategy by combination of E1A gene therapy and paclitaxel chemotherapy (11, 13, 33) . It should be mentioned that the identified molecular mechanism for E1A-induced FOXO3a expression was not observed in the MDA-MB-468 cell line, suggesting that this mechanism might be cell type specific.
We found that E1A can protect FOXO3a from degradation by inhibiting its ubiquitination.
Although previous studies showed that FOXO3a can be targeted by the proteasome pathway after being phosphorylated by Akt or IKK (28, 29). It is worthwhile to mention that FOXO3a was also shown to be phosphorylated by Erk at different sites and the phospho-FOXO3a by Erk can be degraded by an E3 ubiquitin ligase MDM2 (30) . Our data suggest that the ERK signaling pathway may not be involved in E1A-mediated FOXO3a regulation and paclitaxel Foxo3a, unlike AKT and IKK, occurs through MDM2 (30) and E1A can regulate the MDM2 family. For instance, it is known that E1A can bind to MDM4 to inhibit MDM2-induced degradation of p53 (36) . Recently, a study has indicated that ȕTrCP1 oncogenic ubiquitin E3-ligase interacts with FOXO3 and induces its ubiquitin-dependent degradation in an IKKȕ phosphorylation dependent manner (37) . In our study, we found that ȕTrCP can physically bind to FOXO3a and mediate its degradation and that E1A stabilizes FOXO3a by inhibiting the binding of FOXO3a to ȕTrCP. ȕTrCP is the substrate recognition subunits of the Skp1 Cullin1 F-box protein E3 ubiquitin protein ligases that can recognize specifically phosphorylated substrates and confer their ubiquitination. ȕTrCP plays a key role in the NF-țB signaling pathway by recognizing IKK-phosphorylated IțB and mediating its degradation (38) . Our findings revealed a new substrate of ȕTrCP that requires phosphorylation by IKK. Previous studies showed that IKK can phosphorylate FOXO3a at serine 644 and cause FOXO3a nuclear exclusion (29) . Consistent with the other group's study (37), we found that this Ser644 phosphorylation mediated by IKK is also required for FOXO3a binding to ȕTrCP and for the further degradation induced through ȕTrCP. E1A prevents the binding of ȕTrCP to FOXO3a by inhibiting the IKK-mediated FOXO3a phosphorylation at Ser644.
IKK activation requires its phosphorylation by upstream kinases, including TAK1 (39), and phosphorylation plays a significant role in TAK1 activation (40) . We found in this study that E1A inhibits FOXO3a binding to ȕTrCP by preventing TAK1 activation and its effect on IKK activation. It was previously shown that TRAF6 and RIP1 can activate TAK1 and lead to IKK phosphorylation and activation (41, 42) . However, overexpression TRAF6 or RIP1 in E1A-stable cell lines could not restore TAK1 activation and mediate FOXO3a degradation (data not shown), suggesting that prevention of TAK1 activation by E1A is not mediated by those two upstream CAN-11-0295 activators. It is known that PP2A phosphatase activity is enhanced in E1A-expressing cells through E1A-mediated up-regulation of PP2A/C expression, which results in repression of Akt activation (17) . A previous study indicates that PP2A functions as a negative regulator in TGF-ȕ1-induced TAK1 activation (43) . Therefore, E1A-mediated up-regulation of PP2A/C is involved in TAK1 inactivation and inhibits the binding of TAK1 to IKK, which abolishes IKK's function in phosphorylating FOXO3a, resulting in the stabilization of FOXO3a.
The activities of protein kinases are finely regulated by phosphorylation and dephosphorylation, however, little is known about the dephosphorylation and respective protein phosphatase involved in the regulation of TAK1. Protein phosphatase 2A (PP2A) is a ubiquitously expressed protein serine/threonine phosphatase accounts for the tumor suppression activity in eukaryotic cells. Mutation of PP2A was found in human breast, colon, and lung cancers and melanoma (44) . In addition, a variety of mechanisms for inactivating PP2A were found to be involved in transformed cells. PP2A can be inhibited by the small T antigen of the DNA tumor virus SV40 (45), or by upregulation of the c-Myc-specific inhibitor CIP2A (46), or through the upregulation of SET protein by BCR/ABL oncogene (47) . It was previously shown that PP2A can suppress Akt (17) and RalA (48) activation, therefore, inhibit both PI3K/Akt and ERK signaling pathways (49) . We found in this paper that TAK1 is a target of PP2A/C in another important signaling pathway-IKK pathway (50) . Therefore, PP2A may inhibit the three major oncogenic kinase pathways, PI3K/Akt, ERK and IKK, to exert its tumor suppressor activity. E1A, through upregulation of PP2A/C to stimulate PP2A phosphatase activity, may share the same pathways to suppress tumor development. 
